triethylenephosphoramide has been researched along with Breast Cancer in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dang, X; Li, S; Liu, Y; Wu, C; Yang, H; Zhang, J | 1 |
| Di, L; Lyerly, HK; Ren, J; Shao, H; Song, G; Song, Q; Wang, X; Yang, H; Yu, J; Zhou, X; Zhu, X | 1 |
| Beijnen, JH; Doodeman, VD; Ekhart, C; Huitema, AD; Rodenhuis, S; Smits, PH | 1 |
| GRECO, T | 1 |
| Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S; van Dam, SM | 1 |
| Bero, T; Bolovin, LM; Javor, T; Kaplan, MA; Medvedev, VN; Verchovskaja, NI | 1 |
| Beijnen, JH; Huitema, AD; Rodenhuis, S; van Maanen, MJ | 1 |
| Cohen, BE; Egorin, MJ; Gutierrez, PL; Kohlhepp, EA | 1 |
| Aisner, J; Cohen, BE; Egorin, MJ; Gutierrez, PL; Kohlhepp, EA | 1 |
1 trial(s) available for triethylenephosphoramide and Breast Cancer
| Article | Year |
|---|---|
Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
Topics: Adolescent; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Neoplasms; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Phosphoramide Mustards; Prodrugs; Thiotepa; Time Factors; Triethylenephosphoramide | 2005 |
8 other study(ies) available for triethylenephosphoramide and Breast Cancer
| Article | Year |
|---|---|
Copper depletion inhibits CoCl2-induced aggressive phenotype of MCF-7 cells via downregulation of HIF-1 and inhibition of Snail/Twist-mediated epithelial-mesenchymal transition.
Topics: Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cation Transport Proteins; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Polarity; Cobalt; Copper; Copper Transporter 1; Down-Regulation; Epithelial-Mesenchymal Transition; Female; Fibronectins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nuclear Proteins; Phenotype; RNA Interference; RNA, Small Interfering; Signal Transduction; Snail Family Transcription Factors; Transcription Factors; Transcriptional Activation; Transplantation, Heterologous; Triethylenephosphoramide; Twist-Related Protein 1; Vimentin | 2015 |
Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Biotransformation; Breast Neoplasms; Chi-Square Distribution; China; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Disease Progression; Disease-Free Survival; Female; Genotype; Glutathione S-Transferase pi; Humans; Logistic Models; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Odds Ratio; Patient Selection; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Retrospective Studies; Risk Factors; Salvage Therapy; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thiotepa; Time Factors; Treatment Outcome; Triethylenephosphoramide | 2015 |
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Carboplatin; Chromatography, High Pressure Liquid; Cohort Studies; Cyclophosphamide; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Male; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Thiotepa; Triethylenephosphoramide | 2009 |
[Triethylene-phosphoramide or thio-TEPA in therapy of recurrent cancer of the breast].
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasms; Phosphoramides; Thiotepa; Triethylenephosphoramide | 1959 |
[Whole body radiometric study of 59Fe absorption during chemotherapy of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Iron; Iron Radioisotopes; Middle Aged; Thiotepa; Triethylenephosphoramide | 1982 |
Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.
Topics: Acetylcysteine; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Breast Neoplasms; Carboplatin; Creatinine; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Models, Chemical; Neoplasms, Germ Cell and Embryonal; Thiotepa; Time Factors; Triethylenephosphoramide | 2001 |
Gas-liquid chromatographic analysis of N,N',N''-triethylene thiophosphoramide and N,N',N''-triethylene phosphoramide in biological samples.
Topics: Azirines; Breast Neoplasms; Chromatography, Gas; Female; Humans; Kinetics; Middle Aged; Thiotepa; Triethylenephosphoramide | 1985 |
Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatography, Gas; Half-Life; Humans; Hydrogen-Ion Concentration; Kinetics; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Thiotepa; Triethylenephosphoramide | 1986 |